Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Homeobox protein Hox-C4 (HOXC4) is a member of the homeobox family of transcription factors that are essential for morphogenesis and development in multicellular organisms. HOXC4 is encoded by the HOXC4 gene on human chromosome 12, forming part of the HOXC gene cluster. It functions by binding DNA in a sequence-specific manner to regulate gene expression, providing positional identity along the anterior-posterior axis during development. In adults, HOXC4 regulates immune mechanisms by directly activating the AID gene for class switch recombination in B cells, and is implicated in oncogenesis—its overexpression promotes proliferation, glycolysis, and mobility of cancer cells (notably in pancreatic, gastric, hepatocellular carcinoma, and glioma). Dysregulation of HOXC4 is associated with poor prognosis in several cancer types and immune disorders. Downstream, it influences key cell cycle, apoptosis, and metabolic pathways.
Drugs targeting HOXC4 would theoretically act by modulating transcriptional programs controlling cell proliferation, apoptosis, and differentiation; mechanisms may involve influencing glycolytic enzymes or immune functions if such drugs are developed
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Homeobox protein Hox-C4 (HOXC4).